COMP <GO>
INSM vs ALNY // FORWARD P/E MULTIPLE
Insmed Incorporated (NASDAQ) VS. Alnylam Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: INSM 6
— ALNY 6
▲ FORWARD P/E MULTIPLE LEADER: INSM
LAST: $109.31 (-2.90%) • MKT CAP: $24.70B
forward-pe
21.0x
LAST: $158.00 (-4.24%) • MKT CAP: $22.10B
forward-pe
62.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INSM VS. ALNY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INSM | ALNY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 79.70% | 81.80% | -2.10 | ALNY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 21.30% | -56.30 | ALNY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 42.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.97% | 2.00% | -5.97 | ALNY | /fcf-yield <GO> |
| Operating Margin | -60.00% | 13.50% | -73.50 | ALNY | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 8.40% | -68.40 | ALNY | /net-margins <GO> |
| Revenue Growth (YoY) | 66.70% | 65.20% | +1.50 | INSM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.25 | 3.16 | +2.09 | INSM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | ALNY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 62.2 | 25.8 | +36.40 | INSM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.03 | 1.00 | +0.03 | INSM | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 21.0x | 62.3x | -41.30 | INSM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $24.70B | $22.10B | $2.60B | INSM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INSM REV | ALNY REV | INSM GROSS % | ALNY GROSS % | INSM FCF | ALNY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $606.4M | $3.71B | 79.7% | 81.8% | -$967.6M | $465.4M |
| FY 2024 | $363.7M | $2.25B | 76.4% | 86.4% | -$705.8M | -$42.6M |
| FY 2023 | $305.2M | $1.83B | — | — | -$550.0M | $21.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INSM // BETA 1.03
ALNY // BETA 1.00